- Home
- RILYP vs VCEL Comparison
RILYP vs VCEL Comparison
Compare RILYP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RILYP | VCEL |
|---|---|---|
| Founded | 1973 | 1989 |
| Country | United States | United States |
| Employees | 2056 | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | RILYP | VCEL |
|---|---|---|
| Price | $11.18 | $33.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 15.5K | ★ 644.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | ★ $854,383,000.00 | $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | N/A | $17.95 |
| P/E Ratio | ★ N/A | $111.97 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $1.75 | $28.95 |
| 52 Week High | $14.50 | $45.97 |
Technical Indicators
Market Signals| Indicator | RILYP | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 48.78 |
| Support Level | $8.56 | $31.24 |
| Resistance Level | $12.74 | $34.77 |
| Average True Range (ATR) | 0.74 | 1.46 |
| MACD | -0.07 | 0.24 |
| Stochastic Oscillator | 45.00 | 49.86 |
Price Performance
Historical ComparisonAbout RILYP B. Riley Financial Inc.
BRC Group Holdings Inc is a diversified holding company, including financial services, telecom, and retail, and investments in equity, debt and venture capital.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.